1
|
Nicolau P, Mancebo G, Agramunt S, Solé-Sedeño JM, Bellosillo B, Muset MM, Lloveras B, Alameda F, Carreras R. Urine human papillomavirus prevalence in women with high-grade cervical lesions. Eur J Obstet Gynecol Reprod Biol 2014; 183:12-5. [PMID: 25461344 DOI: 10.1016/j.ejogrb.2014.10.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Revised: 09/15/2014] [Accepted: 10/04/2014] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To determine the prevalence of human papillomavirus (HPV) in urine samples from women with high-grade cervical lesions. Secondary objectives are to identify the influence of socio-demographic factors and the different genotypes with urinary HPV positivity. STUDY DESIGN 75 women with a positive biopsy for CIN2+ were included in the study from October 2010 to July 2011. A sample of urine was collected immediately before conization at the outpatient clinic. We analyzed the presence of HPV using a PCR technique. RESULTS The mean age of the patients was 34.8 years (range 24 to 61). All patients had histological CIN2+, of whom 54.67% had CIN3. The prevalence of HPV in urine test was 58.82% in CIN2 population versus 78.05% in CIN3 patients (p 0.072). 31 different genotypes were found. The most frequent HPV genotype was 16-HPV, which was identified in 58% of women with positive HPV-DNA in urine samples. No demographic characteristics were significantly associated to urinary HPV prevalence. CONCLUSION Most of the patients with CIN2+ showed positive results for urine HPV test. The prevalence of positive urinary HPV test was higher for patients with CIN3. HPV urine detection could be considered as an acceptable option for high-risk population who skip regular screening programs.
Collapse
Affiliation(s)
- P Nicolau
- Obstetrics & Gynecology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain.
| | - G Mancebo
- Obstetrics & Gynecology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain; Universitat Autònoma de Barcelona, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - S Agramunt
- Obstetrics & Gynecology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain; IMIM Instituto de Investigación Sanitaria, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - J M Solé-Sedeño
- Obstetrics & Gynecology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - B Bellosillo
- Unit of Molecular Biology, Pathology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain; IMIM Instituto de Investigación Sanitaria, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - M M Muset
- Unit of Molecular Biology, Pathology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - B Lloveras
- Pathology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - F Alameda
- Pathology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain; Universitat Autònoma de Barcelona, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| | - R Carreras
- Obstetrics & Gynecology Department, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain; Universitat Autònoma de Barcelona, Hospital del Mar de Barcelona, Parc Salut Mar. Passeig Marítim 25-29, 08003 Barcelona, Spain
| |
Collapse
|